Original articlePancreas, biliary tract, and liverProton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis
Section snippets
Study Design
We conducted a retrospective cohort study. All patients with HH were reviewed by using the electronic database and medical records at Atrium Medical Centrum Parkstad in Brunssum, a secondary medical center located in the south of Limburg, The Netherlands. Only patients with C282Y homozygosity, which was determined by genetic testing, were included. In a paired group, patients were included when data were available for at least 2 years before and 2 years after the start of PPI treatment. In the
Results
In the paired design, the median length of the recording period before and after the start of PPIs was 3.0 years (interquartile range [IQR], 3.0–3.0). Median SF levels did not differ significantly between the 2 periods (Table 2). In the period before start of PPIs, a total median of 3.16 phlebotomies (IQR, 2.08–3.66) was performed yearly, compared with a median of 0.50 phlebotomies (IQR, 0.00–0.66) per year in the period after start of PPIs. These results differed significantly (P = .002) (
Discussion
Longtime PPI treatment significantly reduces the phlebotomy frequency to maintain the SF level below 100 μg/L in HH patients with C282Y homozygosity, in agreement with the results of the study published by Hutchinson et al.10
These promising results open the way for an alternative add-on medical therapy for patients who need phlebotomies frequently. Administration of PPIs leads to fewer phlebotomies and thus fewer side effects compared with other interventions. Socioeconomic aspects are a
References (21)
- et al.
How I treat hemochromatosis
Blood
(2010) - et al.
Long-term safety concerns with proton pump inhibitors
Am J Med
(2009) EASL clinical practice guidelines for HFE hemochromatosis
J Hepatol
(2010)- et al.
Iron sensing and signalling
Gut
(2012) - et al.
Diagnosis and management of hereditary haemochromatosis
BMJ
(2011) Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment
Gastroenterology
(2010)- et al.
Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment
Transfusion
(2011) - et al.
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases
Hepatology
(2011) Blood donor complications after whole-blood donation
Curr Opin Hematol
(2004)- et al.
Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial
Transfusion
(2012)
Cited by (20)
Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial
2017, GastroenterologyCitation Excerpt :This is the first randomized controlled trial with PPI in HH patients to demonstrate that effect. This study confirms the results of the observational, retrospective studies by Hutchinson and van Aerts.7,8 An important concern in long-term treatment with PPI is the development of side effects.9
A Proton Pump Inhibitor a Day Keeps the Iron Away
2016, Clinical Gastroenterology and HepatologyAbsorption of nonheme iron during gastric acid suppression in patients with hereditary hemochromatosis and healthy controls
2021, American Journal of Physiology - Gastrointestinal and Liver Physiology
Conflicts of interest The authors disclose no conflicts.